JPMorgan Buys In as SLS Surges on Higher Price Target and Institutional Support

Sellas Life Sciences (SLS) shares surged to their strongest close in over a week as new institutional disclosures, clinical timelines, and a higher price target drew investor attention.

The stock jumped 7% on Wednesday but remained on track for a weekly decline, with shares down 2% so far this week. The gains came after Alliance Global lifted its SLS price target to $35 from $25, implying nearly 200% upside.

JPMorgan Chase disclosed a new stake of 100,135 SLS shares valued at $1.48 million as of June 30. Stifel Financial increased its holdings by 883 shares, or nearly 8%, to 12,419 shares worth about $183,300.